Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN).

Trial Profile

Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Sirolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ISAR-LEFT-MAIN
  • Most Recent Events

    • 28 Aug 2010 Data pertaining to the impact on left ventricular function presented at the Annual Congress of the European Society of Cardiology (ESC) 2010.
    • 12 May 2009 Results reported in the Journal of the American College of Cardiology.
    • 20 Oct 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top